The following message has been received by PHSG from Dr Vivek Kodoth, President of Bournemouth Heart Club :
Dr Vivek Kodoth MD FRCP (UK)
Consultant Interventional Cardiologist
The President Bournemouth Heart Club and clinical lead cardiac rehabilitation
University Hospital Dorset, Bournemouth
Poole Heart Support Group members
Subject: Covid vaccine trial
The research department at the Royal Bournemouth Hospital is well-established and regularly conducts national and international multicentre clinical trial. The department strictly follows ethical and national research standards. Today, Researchers worldwide are working round the clock to develop an effective vaccine for Covid-19.
At this stage, a number of vaccine have entered phase-3 clinical trial and one of them is the Novovax nanoparticle vaccine. The Novovax phase 3 trial is being conducted in the United Kingdom (UK), in partnership with the UK Government’s Vaccines Taskforce, and is expected to enrol and immunise up to 10,000 individuals between 18-84 (inclusive) years of age, with and without relevant comorbidities, over the next four to six weeks. The UK Phase 3 clinical trial is a randomized, placebo-controlled, observer-blinded study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 (Novovax) with Matrix-M in up to 10,000 subjects aged 18 to 84 years. Half the participants will receive two intramuscular injections of vaccine comprising 5 µg of protein antigen with 50 µg Matrix‑M adjuvant, administered 21 days apart, while half of the trial participants will receive placebo. The trial is designed to enrol at least 25 percent of participants over the age of 65 as well as to prioritise groups that are most affected by COVID-19, including racial and ethnic minorities.
We are fortunate that the Royal Bournemouth Hospital has been selected as one of the recruiting sites for the vaccine. The recruitment for the trial has begun at the Royal Bournemouth Hospital
If any of the Poole Heart Support Group members are interested to take part in this Covid-19 vaccine research study or would like to know more about this study or future Covid-19 vaccine studies, please contact 03000195311 or email email@example.com
Thank you and keep safe
Dr Vivek Kodoth